India: ‘Patent’ly In Force?

Last Updated: 13 January 2005

By Mustafa Safiyuddin and Ajay Shaw, DSK Legal


Pharmaceutical product patents and patents for computer programs have at last found their way into the Indian patent regime through the Patents Amendment (Ordinance), 2004 promulgated by the President. The expediency of an Ordinance has been resorted to in an endeavour to comply with India’s obligations under Agreement on Trade Related Aspects of Intellectual Property Rights popularly known as "TRIPS" by the January 1, 2005 deadline. However, the Ordinance, seeking to amend the Patents Act, 1970 could lapse if it is not approved by Parliament during the monsoon session. It is questionable as to whether the Government should resort to a Presidential Ordinance bringing about far reaching changes in the patent law without a Parliamentary debate in the first place, in respect of issues on which views have been divided across the country.

The key amendments to the patent regime brought about by the Ordinance and their practical implications may be summarized under the following heads.

Pharmaceutical product patents:

From January 1, 2005, for the first time, the grant of full-fledged pharmaceutical product patents for a term of 20 years will be permissible. Pharmaceutical product patents are advantageous to multinational companies like Pfizer, Glaxco, Novartis and research based Indian drug companies such as Ranbaxy, Dr. Reddy’s and Wockhardt. However, the grant of such product patents may be detrimental to small indigenous generic drug manufacturers.

Further, patents for chemical products and food items are also being introduced. Until now only process patents for pharmaceutical products, chemicals and food items were permissible.

A hybrid system of exclusive marketing rights popularly know as "EMR" for pharmaceutical products had been in place for some time, but is now abolished by the Ordinance in view of the pharmaceutical products patent regime coming into force.

New use patents:

Earlier "new use for a known substance" could not be patented, however, the Ordinance now provides that "mere new use for known substance" cannot be patented. The insertion of a single word "mere" would open the floodgates for pharmaceutical product patents. This is because the word "mere" restricts the scope of non-patentable subject matter and widens the scope of patentability. The effect is that "new pharmaceutical use of a known substance", even though "the substance itself is known and comprises part of the state of the art" would be patentable. Not only first new medical use of known products but also second and subsequent new uses would be patentable. This can be achieved through cleverly drafted "Swiss form" of patent claims. For example, the new discovery that the consumption of the known substance aspirin can also be useful in thinning the blood can be patentable by making a claim for "use of aspirin in making a medicament for use in the prevention of blood clots".

Computer programs:

In an endeavour to encourage the software industry, the scope of patentablity of computer programs has been broadened. This is sought to be achieved by restricting non patentability to "computer programs per se" whilst computer programs’ technical application to industry or a combination with hardware would constitute patentable subject matter. Perhaps the effect is that patents shall not be granted for computer programs in the form of abstract creations lacking in technical character. But patent claims for computer programs having a technical effect may be granted. Thus a computer program product could be patentable if it resulted in additional technical effects that went beyond the ‘normal’ physical interaction between the program (software) and the computer (hardware) on which it was run. With this provision, the standards of patentability of computer programs would perhaps be close to that of the European Union but may not be as liberal as that prevailing in US.

Parallel imports and international exhaustion:

Patent holders often take recourse to the territorial nature of patent rights to prevent parallel imports. Thus if a US patented product is once sold in US, parallel imports thereof into developing countries are sought to be restricted by resorting to legally separate patent rights conferred upon the same product in the developing countries. This anti competitive practice of dividing markets is detrimental to the interests of the developing countries and enables the patentee to earn windfall profits. Through the Ordinance parallel imports into India cannot be prevented by resorting to the above method. This is because India has recognized the "first sale doctrine" also known as the doctrine of "international exhaustion" whereby the patent holder exhausts his rights upon first sale of the patent product in any part of the world and cannot prevent parallel importation thereof by resorting to the patent regime of each country.

Compulsory licensing of pharmaceutical products for exports:

Whilst resorting to the Doha declaration, the Ordinance permits the grant of a compulsory license by the patent authorities (and which may be against the wishes of the patentee) to manufacture and export patented pharmaceutical products from India to countries having insufficient supplies and facing public health problems. This is a departure from the normal rules of compulsory licensing which is permissible primarily to meet the local demands after the expiry of 3 years from the grant of the patent.

Opposition to grant of patent

Prior to grant:

Fundamental changes have been brought about in the opposition procedure with an endeavor to expedite the grant of patents. Earlier any person could oppose the grant of a patent by initiating opposition proceedings and the opponent had a right of audience in such proceeding. Now, under the new procedure, prior to grant of a patent, any person may merely make written representations to the patent authorities against the grant, but has no right of personal hearing.

Post grant:

The earlier law does not provide for any opposition procedure once the patent is granted but only for a right to apply for revocation. The Ordinance now introduces a system of opposition, which can be initiated within a period of one-year post grant of the patent. This is in addition to the revocation procedure which is already in place but only that the same needs to be filed before the newly constituted Appellant Board unless such revocation proceedings are by way of a counter attack in a High Court infringement suit. Since there is already a revocation procedure in place post grant, the need for introducing a new concurrent opposition procedure post grant is perhaps unnecessary.


If the patent regime is implemented in an efficient manner, it can assist India in attracting foreign investments and technology transfers so as to acquire a leadership position in the emerging markets. It can also encourage indigenous research and development.

© DSK Legal, 2005.

The views expressed in this article are those of the authors and do not represent the views of the firm. This article does not purport to be professional advice, nor a complete or comprehensive study on the subject. It is recommended that professional advice be sought before taking any action pursuant to any matter contained in this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.